Skip to main content

Table 2 Pathological distribution of primary tumors and suspected metastases in both cohorts

From: Optimizing acquisition times for total-body positron emission tomography/computed tomography with half-dose 18F-fluorodeoxyglucose in oncology patients

Pathological distribution Primary tumor Lymph node metastasis Distant metastasis
Exploration cohort
Lung (n = 19) 17/1/1 (22) 2/0/0 (2)
Biliary tract (n = 2) 2/0/0 (2) 1/1/0 (3)
Liver (n = 4) 3/1/0 (5) 0/1/0 (2)
Colorectum (n = 17) 17/0/0 (17) 8/3/1 (17)
Stomach (n = 4) 4/0/0 (4) 1/0/0 (1)
Total (n = 46) 50 25 0
Clinical validation cohort
Lung (n = 11) 11/0/0 (11) 1/0/1 (4)
Biliary tract (n = 30) 29/1/0 (31) 11/4/0 (19)
Liver (n = 19) 16/2/1 (23) 2/1/0 (4)
Colorectum (n = 10) 10/0/0 (10) 3/3/2/1 (19) 1/0/2 (7)
Stomach (n = 4) 3/0/1 (6) 2/0/0 (2)
Pancreas (n = 26) 24/2/0 (28) 5/0/0 (5)
Gall bladder (n = 5) 5/0/0 (5) 0/1/1 (5)
Bladder (n = 7) 4/3/0 (10)
Breast (n = 3) 3/0/0 (3) 1/0/0 (1) 1/0/0 (1)
Ovary (n = 4) 3/1/0 (5)
Small intestine (n = 9) 9/0/0 (9) 2/0/0 (2)
Pharynx (n = 3) 3/0/0 (3) 0/0/0/0/0/0/1 (7)
Skin (n = 1) 1/0/0 (1) 1/0/0 (1)
Others (n = 15)* 15/0/0 (15)
Total (n = 147) 160 69 8
  1. Values separated by virgules (/) indicate the number of patients with 1/2/3/4/5/6/7 lesions
  2. Data are numbers of lesions
  3. *Others (n = 15) include the following single primary tumors without metastasis: kidney (n = 4), esophagus (n = 2), mediastinum (n = 3), uterus (n = 1), bones (n = 1), carotid body (n = 1), muscle (n = 1), and retroperitoneum (n = 2)